Uncategorized

Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent

Published

on

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version